This post may contain affiliate links. Read our disclosure policy.
Smith–Lemli–Opitz syndrome disease incidence has been studied, primarily in Europe and Canada. Diagnoses have been confirmed by molecular and biochemical methods. Most figures range from 1/60 00011, 12 to 1/20 000.